Docetaxel + CDDP + 5-FU (DCF)化学療法を受けた

1 JFMC - -C5 EPOC2 study DCF III EPOC2 study Stage International Union Against Cancer TNM classification system, 7th edition 11 2 8 2017 1 2019 8 12 3 2017 1 2019 12 2016 11 7 2016 11 29 2016 12 19 1 0. DCF StageII III DCF Docetaxel , Cisplatin, Fluorouracil + Docetaxel (DOC) 35mg/m2 day1, day15 Cisplatin( cddp ) 40mg/m2 day1, day15 Fluorouracil (5-FU) 400mg/m2 day1-5, day15-19 4 2 2 600kcal /day 8 2 600kcal /day 1 2 1 Docetaxel , Cisplatin, Fluorouracil Docetaxel (DOC) 35mg/m2 day1, day15 Cisplatin( cddp ) 40mg/m2 day1, day15 Fluorouracil (5-FU) 400mg/m2 day1-5, day15-19 4 2 A DCF + B DCF 70 / / day1 3 1 2 Cisplatin( cddp )+Fluorouracil(5-FU) Docetaxel (DOC)

2 Biweekly-DCF Primary Endpoint Grade2 Secondary Endpoint A B CRP Alb Prealbumin ( / ) Grade Kaplan-Maier A B / Grade ( ) Grade2 DCF StageII,III DCF 1) Siewert typeI Tumor type Adeno ca of the distal esophagus I True cardia ca II Subcardial ca III 2 3 DCF UICC TNM 7 StageII,III T4a,T4b T3 102mid 104 3 1 i) ii) iii) iv) v) vi) 210mg/m2 i) T4 102 104 M1 DCF 2nd line ii) StageII,III,IV R1 R2 1st line 2nd line DCF 1st line iii) R1 R2 DCF iv)

3 StageII,III FP DCF 2nd line DCF 1st line StageII,III R1 R2 DCF 1st line DCF 2nd line 1st line DCF 1st line vi) StageII,III DCF 1st line DCF 2nd line 1st line DCF 1st line 2 DCF i) i) 210mg/m2 4 3) 20 75 4) PS ECOG 0 1 5) BSA DuBois 6) 14 2 4,000 /mm3 12,000/mm3 2,000 /mm3 10 104 /mm3 g/dL AST 100 IU/L ALT 100 IU/L mg/dL mg/dL 60 mL/min Cockcroft-Gault 60 mL/min Cockcroft-Gault Ccr= 140 (kg)}/ 72 Cr (mg/dL) Ccr 140 (kg)}/ 72 Cr (mg/dL) 7) Dysphagia score 2 8) Dysphagia score 0 = 1 = 2 = 3 = 4 = / 1) 2) 5 5 3) 4) 1 5) 6)

4 DOC cddp 5-FU 80 7) 8) 38 C 9) 10) CTCAE Grade1 11) CTCAE Grade2 12) CT 13) 14) 15) HCV 16) 17) 1/2 18) (CTCAE )Grade1 19) A -d7 d1 d5 d15 d19 d28 DOC 35mg/m2 cddp 40mg/m2 5-FU 400mg/m2 2 1 d1-28 4 1 2 6 2 A DCF + 1 -d7 1 2 2 2 ( 0 )

5 2 DCF A DCF + 80 B DCF 80 160 A DCF + B DCF 160 7 110 50 2 8 2017 1 2019 8 12 3 2017 1 2019 12 6 7 30